AU Patent

AU2022201294B2 — Methods of treating hfpef employing dapagliflozin and compositions comprising the same

Assigned to AstraZeneca AB · Expires 2024-01-04 · 2y expired

What this patent protects

OF THE DISCLOSURE Methods for treating and/or preventing HFpEF and/or at least one disease, disorder, and/or condition associated therewith in patients by the use of dapagliflozin and compositions comprising the same are disclosed.

USPTO Abstract

OF THE DISCLOSURE Methods for treating and/or preventing HFpEF and/or at least one disease, disorder, and/or condition associated therewith in patients by the use of dapagliflozin and compositions comprising the same are disclosed.

Drugs covered by this patent

Patent Metadata

Patent number
AU2022201294B2
Jurisdiction
AU
Classification
—
Expires
2024-01-04
Drug substance claim
No
Drug product claim
No
Assignee
AstraZeneca AB
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.